Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

January 19, 2017
With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia. Speaking at Biotech Showcase, List explained to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how he is also looking for assets designed to prevent, cure or even intercept the progression of key diseases such as obesity and NASH.
Previous Video
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duva...

Next Video
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the t...